Sodium Hyaluronate Eye Drops Instructions
Release time:
2020-07-07
Approval Date: May 21, 2007
Revision Date: December 21, 2010
Peak
Sodium Hyaluronate Eye Drops Instructions
[Drug Name]
General Name: Sodium Hyaluronate Eye Drops
English Name: Sodium Hyaluronate Hyaluronate Eye Drops
Chinese Pinyin: Bolisuanna Diyanye
[Ingredients]
The main ingredient of this product is sodium hyaluronate.
Chemical Name:(1 → 4)-O-β-D-Glucuronic Acid-(1 → 3)-2-Acetylamino -2-Deoxy-β-D-Glucose
Molecular Formula:(C14H20NNaO11)n
[Character] This product is a colorless and clear slightly viscous liquid.
[Indications]
is used for keratoconjunctival epithelial injury caused by internal diseases such as Sjogren's syndrome (Sjogren,s syndrome), Sjogren's syndrome (Stevens-Johnson syndrome), dry eye (dry eye) and various external diseases (such as surgery, drug-induced, trauma, wearing contact lenses, etc.). It is especially suitable for patients with Sjogren's syndrome and Sjogren's syndrome requiring long-term medication.
[Specification] 5ml:5mg(0.1%)
[Usage and Dosage]
Eye drops, usually 1 drop at a time, 5-6 times a day, can be appropriately increased or decreased according to symptoms. Generally, 0.1% of the preparation is used, and 0.3% of the preparation is used in cases where the effect is not good.
[Adverse Reactions]
(1) Sometimes corneal disorders such as itching, irritation, congestion, and diffuse superficial keratitis may occur. If the above symptoms occur, the medication should be stopped immediately.
(2) Allergy: Occasional blepharitis, blepharitis and other allergic symptoms, such as allergy, should immediately stop medication.
[Taboo] is not clear.
[Precautions]
This product is only used for eye drops. Be careful not to contact the mouth of the eye drop bottle with the eye when dropping the eye. Please close the bottle cap tightly after use. After opening, do not use the soft contact lens without removing it.
[Use in pregnant and lactating women] is not clear.
Pediatric use is not clear.
[Geriatric use] is not clear.
Drug interaction is not clear.
Overdose is unknown.
[Pharmacology and Toxicology]
Sodium hyaluronate is a natural polymer compound, which is an important component of tissue matrix. It has good viscoelasticity and has a protective effect on cornea. Combined with fibronectin, it promotes the connection and extension of corneal epithelial cells and accelerates corneal wound healing. In addition, sodium hyaluronate molecules have strong hydrophilic ability and lubrication, which can stabilize the tear film, prevent keratoconjunctival dryness and reduce the friction of eye tissue, and relieve the discomfort symptoms of dry eye.
[Pharmacokinetics]
After 14C-labeled 0.1 sodium hyaluronate eye drops are instilled in rabbits, strong radioactivity can be detected in conjunctiva, external eye muscle and sclera within 0.5h, with the strongest radioactivity in conjunctiva, weak radioactivity can be detected in cornea, retina and choroid, while no radioactivity can be detected in aqueous humor, iris, ciliary body, crystal and vitreous. The radioactivity of the conjunctiva dropped below the threshold after 24h. Healthy people were given 0.1 sodium hyaluronate eye drops on the first day of monocular eyes, and were changed to 0.5 sodium hyaluronate eye drops on the second day, 1 drop once, 5 times a day, and continued to use sodium hyaluronate eye drops on the third to ninth days, 13 times a day, for 7 consecutive days. The concentration of sodium hyaluronate in serum was determined at the beginning of the drop, on the third day, the ninth day and the tenth day, and all of them were below the detection limit (10?g/ml), which was the same as that of the drop.
[Storage] Shade and place in a cool place (not more than 20 ℃).
[packaging] plastic bottles, 5ml per bottle.
[Validity Period] 24 Months
[Implementation Standard] YBH04002006
[Approval Document Number] National Medicine Standard H20063950
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: 368 Jinqu Road, Jinhua Industrial Park, Zhejiang Province Zip Code: 321016
Tel: 0579-82273183
Fax: 0579-82272272
Website:
www.zjjy.com.cn
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page